首页 > 最新文献

Frontiers in Cardiovascular Medicine最新文献

英文 中文
Cardioneuroablation eliminating cardiac asystole associated with area postrema syndrome: a case report and literature review. 心脏神经消融术消除了与后遗区综合征相关的心脏骤停:病例报告和文献综述。
IF 2.8 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-31 eCollection Date: 2024-01-01 DOI: 10.3389/fcvm.2024.1453166
EnRun Wang, YuanJing Li, Gang Yu, Gang Liu, Jiang Deng, YanFei Wang, Wei Yang, GuoDong Chen, Dennis W Zhu, FengPeng Jia

Background: There have been few instances of symptomatic bradycardia-arrhythmia in the context of area postrema syndrome (APS), and some of them have been implanted permanent pacemakers. Cardioneuroablation (CNA) has emerged as a viable therapy for the treatment of syncope induced by neutrally mediated bradycardia or atrioventricular block.

Methods: We report a young patient with recurrent cardiac asystole and syncope following persistent hiccups caused by neuromyelitis optica spectrum disorder (NMOSD), who successfully completed CNA treatment and avoided permanent pacemaker placement. We also summarized and analyzed 20 previously reported cases that were relevant to APS with bradyarrhythmia.

Results: In a patient with NMOSD, CNA can efficiently and safely eradicate symptomatic bradycardia-arrhythmia. A total of 21 cases were identified in the final analysis (including our case). The average age was 51 years old and female patients accounted for 38.1%. Brady-arrhythmia was presented in all patients, and 9 patients were implanted temporary or permanent pacemakers. 4 of the 9 patients were received permanent pacing therapy because they were not weaned off pacing support after etiological treatment.

Conclusions: Cardiac asystole and syncope after persistent hiccups may be the first signs of APS of medullary lesions, and CNA may be a useful therapy option for these patients in experienced centers. We believe that in this scenario, CNA may be a superior therapeutic option than permanent pacemaker placement. Additionally, the statement also serves as a cautionary reminder for health care professionals to establish an association between bradyarrhythmia and APS of medullary lesions in their clinical practice.

背景:很少有症状性心动过缓-心律失常并发症(APS),其中一些患者已植入永久性心脏起搏器。心脏神经消融术(CNA)已成为治疗中性介导的心动过缓或房室传导阻滞引起的晕厥的一种可行疗法:我们报告了一名因神经脊髓炎视神经谱系障碍(NMOSD)引起的持续性打嗝而反复出现心脏停搏和晕厥的年轻患者,该患者成功完成了 CNA 治疗,避免了永久性起搏器的安置。我们还总结并分析了之前报道的与伴有缓慢性心律失常的 APS 相关的 20 个病例:结果:对于 NMOSD 患者,CNA 可以有效、安全地消除症状性心动过缓和心律失常。最终分析共发现 21 个病例(包括我们的病例)。平均年龄为 51 岁,女性患者占 38.1%。所有患者均出现过缓性心律失常,9 名患者植入了临时或永久起搏器。9名患者中有4人接受了永久起搏治疗,因为他们在病因治疗后没有脱离起搏支持:结论:持续打嗝后的心搏骤停和晕厥可能是髓质病变 APS 的首发症状,在有经验的中心,CNA 可能是这些患者的有效治疗选择。我们认为,在这种情况下,CNA 可能是比安置永久起搏器更优越的治疗方案。此外,该声明还提醒医护人员在临床实践中应将缓慢性心律失常与髓质病变 APS 联系起来。
{"title":"Cardioneuroablation eliminating cardiac asystole associated with area postrema syndrome: a case report and literature review.","authors":"EnRun Wang, YuanJing Li, Gang Yu, Gang Liu, Jiang Deng, YanFei Wang, Wei Yang, GuoDong Chen, Dennis W Zhu, FengPeng Jia","doi":"10.3389/fcvm.2024.1453166","DOIUrl":"10.3389/fcvm.2024.1453166","url":null,"abstract":"<p><strong>Background: </strong>There have been few instances of symptomatic bradycardia-arrhythmia in the context of area postrema syndrome (APS), and some of them have been implanted permanent pacemakers. Cardioneuroablation (CNA) has emerged as a viable therapy for the treatment of syncope induced by neutrally mediated bradycardia or atrioventricular block.</p><p><strong>Methods: </strong>We report a young patient with recurrent cardiac asystole and syncope following persistent hiccups caused by neuromyelitis optica spectrum disorder (NMOSD), who successfully completed CNA treatment and avoided permanent pacemaker placement. We also summarized and analyzed 20 previously reported cases that were relevant to APS with bradyarrhythmia.</p><p><strong>Results: </strong>In a patient with NMOSD, CNA can efficiently and safely eradicate symptomatic bradycardia-arrhythmia. A total of 21 cases were identified in the final analysis (including our case). The average age was 51 years old and female patients accounted for 38.1%. Brady-arrhythmia was presented in all patients, and 9 patients were implanted temporary or permanent pacemakers. 4 of the 9 patients were received permanent pacing therapy because they were not weaned off pacing support after etiological treatment.</p><p><strong>Conclusions: </strong>Cardiac asystole and syncope after persistent hiccups may be the first signs of APS of medullary lesions, and CNA may be a useful therapy option for these patients in experienced centers. We believe that in this scenario, CNA may be a superior therapeutic option than permanent pacemaker placement. Additionally, the statement also serves as a cautionary reminder for health care professionals to establish an association between bradyarrhythmia and APS of medullary lesions in their clinical practice.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1453166"},"PeriodicalIF":2.8,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predicting major adverse cardiovascular events in angina patients using radiomic features of pericoronary adipose tissue based on CCTA. 利用基于 CCTA 的冠状动脉周围脂肪组织放射学特征预测心绞痛患者的主要不良心血管事件。
IF 2.8 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-31 eCollection Date: 2024-01-01 DOI: 10.3389/fcvm.2024.1462451
Weisheng Zhan, Yanfang Luo, Hui Luo, Zheng Zhou, Nianpei Yin, Yixin Li, Xinyi Feng, Ying Yang

Objective: This study aims to evaluate whether radiomic features of pericoronary adipose tissue (PCAT) derived from coronary computed tomography angiography (CCTA) can better predict major adverse cardiovascular events (MACE) in patients with angina pectoris.

Methods: A single-center retrospective study included 239 patients with angina pectoris who underwent coronary CT examinations. Participants were divided into MACE (n = 46) and non-MACE (n = 193) groups based on the occurrence of MACE during follow-up, and further allocated into a training cohort (n = 167) and a validation cohort (n = 72) at a 7:3 ratio. Automatic segmentation of PCAT surrounding the proximal segments of the left anterior descending artery (LAD), left circumflex coronary artery (LCX), and right coronary artery (RCA) was performed for all patients. Radiomic features of the coronary arteries were extracted, screened, and integrated while quantifying the fat attenuation index (FAI) for the three vessels. Univariate and multivariate logistic regression analyses were utilized to select clinical predictors of adverse cardiovascular events. Subsequently, machine learning techniques were employed to construct models based on FAI, clinical features, and radiomic characteristics. The predictive performance of each model was assessed and compared using receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis for clinical utility.

Results: The radiomics model demonstrated superior performance in predicting MACE in patients with angina pectoris within both the training and validation cohorts, yielding areas under the curve (AUC) of 0.83 and 0.71, respectively, which significantly outperformed the FAI model (AUC = 0.71, 0.54) and the clinical model (AUC = 0.81, 0.67), with statistically significant differences in AUC (p < 0.05). Calibration curves for all three predictive models exhibited good fit (all p > 0.05). Decision curve analysis indicated that the radiomics model provided higher clinical benefit than the traditional clinical and FAI models.

Conclusion: The CCTA-based PCAT radiomics model is an effective tool for predicting MACE in patients with angina pectoris, assisting clinicians in optimizing risk stratification for individual patients. The CCTA-based radiomics model significantly surpasses traditional FAI and clinical models in predicting major adverse cardiovascular events in patients with angina pectoris.

研究目的本研究旨在评估冠状动脉计算机断层扫描(CCTA)得出的冠状动脉周围脂肪组织(PCAT)的放射学特征是否能更好地预测心绞痛患者的主要不良心血管事件(MACE):一项单中心回顾性研究纳入了239名接受冠状动脉CT检查的心绞痛患者。根据随访期间MACE的发生情况,将参与者分为MACE组(n = 46)和非MACE组(n = 193),并按7:3的比例进一步分为训练组(n = 167)和验证组(n = 72)。对所有患者的左前降支动脉(LAD)、左冠状动脉(LCX)和右冠状动脉(RCA)近端周围的 PCAT 进行自动分割。提取、筛选和整合冠状动脉的放射学特征,同时量化三条血管的脂肪衰减指数(FAI)。利用单变量和多变量逻辑回归分析筛选出不良心血管事件的临床预测因素。随后,利用机器学习技术构建了基于 FAI、临床特征和放射学特征的模型。利用接收器操作特征曲线(ROC)、校准图和决策曲线分析对每个模型的预测性能进行了评估和比较,以确定其临床实用性:结果:放射组学模型在预测训练组和验证组心绞痛患者的MACE方面表现优异,曲线下面积(AUC)分别为0.83和0.71,明显优于FAI模型(AUC = 0.71,0.54)和临床模型(AUC = 0.81,0.67),AUC差异具有统计学意义(P > 0.05)。决策曲线分析表明,与传统的临床模型和 FAI 模型相比,放射组学模型能提供更高的临床获益:结论:基于 CCTA 的 PCAT 放射组学模型是预测心绞痛患者 MACE 的有效工具,可帮助临床医生优化患者的风险分层。在预测心绞痛患者的主要不良心血管事件方面,基于 CCTA 的放射组学模型明显优于传统的 FAI 模型和临床模型。
{"title":"Predicting major adverse cardiovascular events in angina patients using radiomic features of pericoronary adipose tissue based on CCTA.","authors":"Weisheng Zhan, Yanfang Luo, Hui Luo, Zheng Zhou, Nianpei Yin, Yixin Li, Xinyi Feng, Ying Yang","doi":"10.3389/fcvm.2024.1462451","DOIUrl":"10.3389/fcvm.2024.1462451","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to evaluate whether radiomic features of pericoronary adipose tissue (PCAT) derived from coronary computed tomography angiography (CCTA) can better predict major adverse cardiovascular events (MACE) in patients with angina pectoris.</p><p><strong>Methods: </strong>A single-center retrospective study included 239 patients with angina pectoris who underwent coronary CT examinations. Participants were divided into MACE (<i>n</i> = 46) and non-MACE (<i>n</i> = 193) groups based on the occurrence of MACE during follow-up, and further allocated into a training cohort (<i>n</i> = 167) and a validation cohort (<i>n</i> = 72) at a 7:3 ratio. Automatic segmentation of PCAT surrounding the proximal segments of the left anterior descending artery (LAD), left circumflex coronary artery (LCX), and right coronary artery (RCA) was performed for all patients. Radiomic features of the coronary arteries were extracted, screened, and integrated while quantifying the fat attenuation index (FAI) for the three vessels. Univariate and multivariate logistic regression analyses were utilized to select clinical predictors of adverse cardiovascular events. Subsequently, machine learning techniques were employed to construct models based on FAI, clinical features, and radiomic characteristics. The predictive performance of each model was assessed and compared using receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis for clinical utility.</p><p><strong>Results: </strong>The radiomics model demonstrated superior performance in predicting MACE in patients with angina pectoris within both the training and validation cohorts, yielding areas under the curve (AUC) of 0.83 and 0.71, respectively, which significantly outperformed the FAI model (AUC = 0.71, 0.54) and the clinical model (AUC = 0.81, 0.67), with statistically significant differences in AUC (<i>p</i> < 0.05). Calibration curves for all three predictive models exhibited good fit (all <i>p</i> > 0.05). Decision curve analysis indicated that the radiomics model provided higher clinical benefit than the traditional clinical and FAI models.</p><p><strong>Conclusion: </strong>The CCTA-based PCAT radiomics model is an effective tool for predicting MACE in patients with angina pectoris, assisting clinicians in optimizing risk stratification for individual patients. The CCTA-based radiomics model significantly surpasses traditional FAI and clinical models in predicting major adverse cardiovascular events in patients with angina pectoris.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1462451"},"PeriodicalIF":2.8,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560751/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blood pressure and hypertension in older adults with a history of regular cannabis use: findings from the Multi-Ethnic Study of Atherosclerosis. 有定期吸食大麻史的老年人的血压和高血压:多种族动脉粥样硬化研究的发现。
IF 2.8 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-30 eCollection Date: 2024-01-01 DOI: 10.3389/fcvm.2024.1432923
Jamie Corroon, Ryan Bradley, Matthew A Allison, Igor Grant

Background: Observational evidence investigating associations between cannabis use and blood pressure and hypertension is inconsistent.

Methods: Cross-sectional data from 3,255 participants at Exam 6 (2016-2018) of the Multi-Ethnic Study of Atherosclerosis (MESA) were analyzed, including self-reported cannabis smoking patterns, standardized measures of systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP; BP collectively), and hypertension. ANCOVA and multivariable relative risk regression models were used to calculate adjusted means for BP and adjusted prevalence ratios (PRs) for prevalent hypertension.

Results: In fully adjusted ANCOVA models, a history of regular cannabis smoking, when compared to no history, was not significantly associated with increased SBP [mean difference: 0.1 mmHg (95% CI: -1.6-1.9)], DBP [mean difference: 0.5 mmHg (95% CI: -0.3-1.4)], PP [mean difference: -0.5 mmHg (95% CI: -1.8-0.9)], or prevalent hypertension [PR: 1.01 (95% CI: 0.93-1.10)]. Furthermore, no associations were observed for either the duration or recency (in the past month) of cannabis smoking or number of joint/pipe years. Models exploring potential interactions between a history of regular cannabis smoking and age, sex, race/ethnicity, and cigarette smoking status were not significant for either BP or hypertension.

Conclusions: In a cohort of racially and ethnically diverse older adults with a high prevalence of hypertension, no evidence of increased risk due to regular cannabis smoking was found for either blood pressure or hypertension.

背景:调查大麻使用与血压和高血压之间关系的观察证据并不一致:分析了多种族动脉粥样硬化研究(MESA)第 6 次检查(2016-2018 年)中 3255 名参与者的横断面数据,包括自我报告的大麻吸食模式、收缩压 (SBP)、舒张压 (DBP)、脉压 (PP; BP 合计) 的标准化测量值和高血压。采用方差分析和多变量相对风险回归模型计算调整后的血压平均值和调整后的高血压患病率(PR):在完全调整的方差分析模型中,与没有吸食大麻史相比,经常吸食大麻史与 SBP [平均差异:0.1 毫米汞柱(95% CI:-1.6-1.9)]、DBP [平均差异:0.5 毫米汞柱(95% CI:-0.3-1.4)]、PP [平均差异:-0.5 毫米汞柱(95% CI:-1.8-0.9)] 或高血压患病率 [PR: 1.01 (95% CI: 0.93-1.10)]的升高没有显著关系。此外,没有观察到吸食大麻的持续时间或最近一次(过去一个月内)或关节/管道年数有任何关联。探索定期吸食大麻史与年龄、性别、种族/民族和吸烟状况之间潜在相互作用的模型对血压或高血压均无显著影响:在一群高血压发病率较高的不同种族和民族的老年人中,没有发现经常吸食大麻会增加血压或高血压风险的证据。
{"title":"Blood pressure and hypertension in older adults with a history of regular cannabis use: findings from the Multi-Ethnic Study of Atherosclerosis.","authors":"Jamie Corroon, Ryan Bradley, Matthew A Allison, Igor Grant","doi":"10.3389/fcvm.2024.1432923","DOIUrl":"10.3389/fcvm.2024.1432923","url":null,"abstract":"<p><strong>Background: </strong>Observational evidence investigating associations between cannabis use and blood pressure and hypertension is inconsistent.</p><p><strong>Methods: </strong>Cross-sectional data from 3,255 participants at Exam 6 (2016-2018) of the Multi-Ethnic Study of Atherosclerosis (MESA) were analyzed, including self-reported cannabis smoking patterns, standardized measures of systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP; BP collectively), and hypertension. ANCOVA and multivariable relative risk regression models were used to calculate adjusted means for BP and adjusted prevalence ratios (PRs) for prevalent hypertension.</p><p><strong>Results: </strong>In fully adjusted ANCOVA models, a history of regular cannabis smoking, when compared to no history, was not significantly associated with increased SBP [mean difference: 0.1 mmHg (95% CI: -1.6-1.9)], DBP [mean difference: 0.5 mmHg (95% CI: -0.3-1.4)], PP [mean difference: -0.5 mmHg (95% CI: -1.8-0.9)], or prevalent hypertension [PR: 1.01 (95% CI: 0.93-1.10)]. Furthermore, no associations were observed for either the duration or recency (in the past month) of cannabis smoking or number of joint/pipe years. Models exploring potential interactions between a history of regular cannabis smoking and age, sex, race/ethnicity, and cigarette smoking status were not significant for either BP or hypertension.</p><p><strong>Conclusions: </strong>In a cohort of racially and ethnically diverse older adults with a high prevalence of hypertension, no evidence of increased risk due to regular cannabis smoking was found for either blood pressure or hypertension.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1432923"},"PeriodicalIF":2.8,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11557345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of Danlou tablets in the treatment of stable angina pectoris with intermingled phlegm and blood stasis syndrome in coronary heart disease: a multicenter randomized controlled study. 多中心随机对照研究:丹络片治疗冠心病稳定型心绞痛痰瘀互结综合征的有效性和安全性。
IF 2.8 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-30 eCollection Date: 2024-01-01 DOI: 10.3389/fcvm.2024.1462730
Zeng Li, Han Li, Zheng Li, Yushi Zhou, Wei Yang, Yuhan Ao, Xinghua Xiang, Chongchai Li, Mingxue Zhang
<p><strong>Objectives: </strong>In this study, we assessed the clinical efficacy and safety of Danlou tablets in the treatment of stable angina pectoris (SAP) with intermingled phlegm and blood stasis (IPBS), to provide high-quality evidence-based medical evidence for the prevention and treatment of coronary heart disease.</p><p><strong>Methods: </strong>In this multicenter randomized controlled study, 304 patients diagnosed with stable angina pectoris with IPBS enrolled from 12 national traditional Chinese medicine (TCM) clinical research centers in China were randomly assigned to the treatment group and the control group at a ratio of 1:1. Each group was divided into four subgroups based on the results of TCM syndrome differentiation: IPBS, IPBS combined with qi deficiency, IPBS combined with qi stagnation, and IPBS combined with toxin accumulation. The control group was treated with routine Western medicine. In addition to routine Western medicine treatment, the treatment group (the IPBS group) was treated with Danlou tablets or Danlou tablets supplemented by interventional therapies based on the results of traditional Chinese medicine differentiation. The frequency of angina attacks per week was the main efficacy evaluation indicator and the secondary efficacy evaluation indicators included angina symptom score, Seattle Angina Questionnaire, an electrocardiogram (ECG) efficacy evaluation, a cardiac Doppler two-dimensional ultrasound, an electrocardiogram treadmill exercise test, blood lipids, blood glucose, a coagulation function test, hemorheology indicators, homocysteine, C-reactive protein (CRP) or high sensitivity-CRP, TCM syndromes (syndrome score, tongue, pulse), and long-term prognosis (endpoint outcome, cardiovascular events).</p><p><strong>Results: </strong>There were 300 cases in the full analysis set (FAS), 266 in the per-protocol set (PPS), and 300 in the safety set. Regarding the main efficacy indicator, after treatment, the reduction in the frequency of weekly angina attacks in the treatment group was significantly greater than that in the control group (<i>P</i> < 0.05). The results of the FAS and PPS were consistent. Regarding the secondary efficacy evaluation indicators, the angina symptom, TCM syndrome, ECG evaluation, Seattle Angina Pectoris Questionnaire, and 36-item Health Status Survey Summary Form scores of the treatment group were significantly higher than the control group (<i>P</i> < 0.05) and the homocysteine levels of the treatment group were significantly reduced (<i>P</i> < 0.05). The results of the FAS and PPS were consistent. In the PPS, the triglyceride levels in the treatment group were significantly lower than those in the control group after treatment (<i>P</i> < 0.05). The activated partial thromboplastin time in the treatment group decreased significantly (<i>P</i> < 0.05). There was no statistically significant difference in the safety indicators and incidence of adverse reactions between the two groups.
研究目的本研究评估了丹路片治疗痰瘀互结型稳定性心绞痛(SAP)的临床疗效和安全性,为冠心病的防治提供高质量的循证医学证据:在这项多中心随机对照研究中,来自中国12个国家中医临床研究中心的304名稳定型心绞痛伴痰瘀互结(IPBS)患者被随机分配到治疗组和对照组,两组的比例为1:1。每组根据中医证候分型结果分为四个亚组:IPBS、IPBS 合并气虚、IPBS 合并气滞、IPBS 合并毒素蓄积。对照组采用常规西药治疗。治疗组(IPBS 组)在常规西医治疗的基础上,根据中医分型结果,采用丹路片或丹路片辅以介入疗法进行治疗。主要疗效评价指标为每周心绞痛发作频率,次要疗效评价指标包括心绞痛症状评分、西雅图心绞痛问卷、心电图疗效评价、心脏多普勒二维超声检查、心电图跑步训练、心电图跑步机运动测试、血脂、血糖、凝血功能测试、血液流变学指标、同型半胱氨酸、C反应蛋白(CRP)或高敏CRP、中医综合征(综合征评分、舌象、脉象)和长期预后(终点结局、心血管事件)。结果:全分析组(FAS)有 300 例,按方案组(PPS)有 266 例,安全组有 300 例。在主要疗效指标方面,治疗后,治疗组心绞痛每周发作次数的减少幅度明显高于对照组(P P P P P 结论:治疗组心绞痛每周发作次数的减少幅度明显高于对照组(P P P P P 结论:治疗组心绞痛每周发作次数的减少幅度明显高于对照组(P P P P P丹鹿片和基于西医治疗的改良联合疗法能改善 SAP 和 IPBS 综合征及其并发症患者的心绞痛症状,提高患者的生活质量。临床试验注册:https://www.chictr.org.cn/showproj.html?proj=39724,ChiCTR注册,ChiCTR1900023708。
{"title":"Efficacy and safety of Danlou tablets in the treatment of stable angina pectoris with intermingled phlegm and blood stasis syndrome in coronary heart disease: a multicenter randomized controlled study.","authors":"Zeng Li, Han Li, Zheng Li, Yushi Zhou, Wei Yang, Yuhan Ao, Xinghua Xiang, Chongchai Li, Mingxue Zhang","doi":"10.3389/fcvm.2024.1462730","DOIUrl":"10.3389/fcvm.2024.1462730","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objectives: &lt;/strong&gt;In this study, we assessed the clinical efficacy and safety of Danlou tablets in the treatment of stable angina pectoris (SAP) with intermingled phlegm and blood stasis (IPBS), to provide high-quality evidence-based medical evidence for the prevention and treatment of coronary heart disease.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;In this multicenter randomized controlled study, 304 patients diagnosed with stable angina pectoris with IPBS enrolled from 12 national traditional Chinese medicine (TCM) clinical research centers in China were randomly assigned to the treatment group and the control group at a ratio of 1:1. Each group was divided into four subgroups based on the results of TCM syndrome differentiation: IPBS, IPBS combined with qi deficiency, IPBS combined with qi stagnation, and IPBS combined with toxin accumulation. The control group was treated with routine Western medicine. In addition to routine Western medicine treatment, the treatment group (the IPBS group) was treated with Danlou tablets or Danlou tablets supplemented by interventional therapies based on the results of traditional Chinese medicine differentiation. The frequency of angina attacks per week was the main efficacy evaluation indicator and the secondary efficacy evaluation indicators included angina symptom score, Seattle Angina Questionnaire, an electrocardiogram (ECG) efficacy evaluation, a cardiac Doppler two-dimensional ultrasound, an electrocardiogram treadmill exercise test, blood lipids, blood glucose, a coagulation function test, hemorheology indicators, homocysteine, C-reactive protein (CRP) or high sensitivity-CRP, TCM syndromes (syndrome score, tongue, pulse), and long-term prognosis (endpoint outcome, cardiovascular events).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;There were 300 cases in the full analysis set (FAS), 266 in the per-protocol set (PPS), and 300 in the safety set. Regarding the main efficacy indicator, after treatment, the reduction in the frequency of weekly angina attacks in the treatment group was significantly greater than that in the control group (&lt;i&gt;P&lt;/i&gt; &lt; 0.05). The results of the FAS and PPS were consistent. Regarding the secondary efficacy evaluation indicators, the angina symptom, TCM syndrome, ECG evaluation, Seattle Angina Pectoris Questionnaire, and 36-item Health Status Survey Summary Form scores of the treatment group were significantly higher than the control group (&lt;i&gt;P&lt;/i&gt; &lt; 0.05) and the homocysteine levels of the treatment group were significantly reduced (&lt;i&gt;P&lt;/i&gt; &lt; 0.05). The results of the FAS and PPS were consistent. In the PPS, the triglyceride levels in the treatment group were significantly lower than those in the control group after treatment (&lt;i&gt;P&lt;/i&gt; &lt; 0.05). The activated partial thromboplastin time in the treatment group decreased significantly (&lt;i&gt;P&lt;/i&gt; &lt; 0.05). There was no statistically significant difference in the safety indicators and incidence of adverse reactions between the two groups.","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1462730"},"PeriodicalIF":2.8,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mitochondrial dysfunction is a key link involved in the pathogenesis of sick sinus syndrome: a review. 线粒体功能障碍是病窦综合征发病机制中的关键环节:综述。
IF 2.8 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-29 eCollection Date: 2024-01-01 DOI: 10.3389/fcvm.2024.1488207
Xinxin Shi, Liming He, Yucheng Wang, Yue Wu, Dongming Lin, Chao Chen, Ming Yang, Shuwei Huang

Sick sinus syndrome (SSS) is a grave medical condition that can precipitate sudden death. The pathogenesis of SSS remains incompletely understood. Existing research postulates that the fundamental mechanism involves increased fibrosis of the sinoatrial node and its surrounding tissues, as well as disturbances in the coupled-clock system, comprising the membrane clock and the Ca2+ clock. Mitochondrial dysfunction exacerbates regional tissue fibrosis and disrupts the functioning of both the membrane and calcium clocks. This plays a crucial role in the underlying pathophysiology of SSS, including mitochondrial energy metabolism disorders, mitochondrial oxidative stress damage, calcium overload, and mitochondrial quality control disorders. Elucidating the mitochondrial mechanisms involved in the pathophysiology of SSS and further investigating the disease's mechanisms is of great significance.

病窦综合征(SSS)是一种可导致猝死的严重疾病。病态窦房结综合征的发病机制尚未完全明了。现有研究推测,其基本机制包括窦房结及其周围组织纤维化加重,以及由膜时钟和 Ca2+ 时钟组成的耦合时钟系统紊乱。线粒体功能障碍会加剧区域组织纤维化,并破坏膜时钟和钙时钟的功能。这在 SSS 的潜在病理生理学中起着至关重要的作用,包括线粒体能量代谢紊乱、线粒体氧化应激损伤、钙超载和线粒体质量控制紊乱。阐明参与 SSS 病理生理学的线粒体机制并进一步研究该疾病的机制具有重要意义。
{"title":"Mitochondrial dysfunction is a key link involved in the pathogenesis of sick sinus syndrome: a review.","authors":"Xinxin Shi, Liming He, Yucheng Wang, Yue Wu, Dongming Lin, Chao Chen, Ming Yang, Shuwei Huang","doi":"10.3389/fcvm.2024.1488207","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1488207","url":null,"abstract":"<p><p>Sick sinus syndrome (SSS) is a grave medical condition that can precipitate sudden death. The pathogenesis of SSS remains incompletely understood. Existing research postulates that the fundamental mechanism involves increased fibrosis of the sinoatrial node and its surrounding tissues, as well as disturbances in the coupled-clock system, comprising the membrane clock and the Ca<sup>2+</sup> clock. Mitochondrial dysfunction exacerbates regional tissue fibrosis and disrupts the functioning of both the membrane and calcium clocks. This plays a crucial role in the underlying pathophysiology of SSS, including mitochondrial energy metabolism disorders, mitochondrial oxidative stress damage, calcium overload, and mitochondrial quality control disorders. Elucidating the mitochondrial mechanisms involved in the pathophysiology of SSS and further investigating the disease's mechanisms is of great significance.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1488207"},"PeriodicalIF":2.8,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554481/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bibliometric analysis of imaging and treatment strategies for severe tricuspid regurgitation from 2015 to 2023. 2015年至2023年严重三尖瓣反流的成像和治疗策略文献计量分析。
IF 2.8 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-29 eCollection Date: 2024-01-01 DOI: 10.3389/fcvm.2024.1444466
Johannes Schlegl, Marwin Bannehr, Tanja Kücken, Paulina Jankowska, Michael Neuss, Michael Lichtenauer, Anja Haase-Fielitz, Christian Butter, Christoph Edlinger

Background: Severe tricuspid regurgitation is a progressive disease with an unfavourable prognosis. In recent years there have been extraordinary gains in knowledge through both clinical and basic scientific work. We performed a bibliometric analysis on tricuspid regurgitation with a focus on imaging techniques and treatment approaches and to identify scientific milestones and emerging research trends.

Methods: Publications, published between 2015 and 2023 were identified. Study characteristics, impact factors and countries of origin studies were recorded. Heat maps were created to visualise data and to identify leading centers. Most frequently cited publications were recognised as milestones.

Results: We screened 3,519 studies. 368 studies were included, of which 326 were clinical studies. Clinical studies were further subdivided into interventional (n = 138), surgical (n = 115) or studies on imaging modalities (n = 74). We detected an enormous increase in scientific output worldwide, especially in imaging and interventional studies. The United States, Germany and Poland were identified as leading countries in imaging, interventions and preclinical studies respectively.

Conclusions: Our study reflects the global gain in knowledge over the last 9 years. We were able to identify an annually rising number of interventional studies. Imaging studies have also seen a rapid increase, especially since 2020. In recent years, we monitored a decline in surgical studies.

背景:严重三尖瓣反流是一种进展性疾病,预后不良。近年来,临床和基础科学研究都取得了非凡的成就。我们对三尖瓣反流进行了文献计量分析,重点关注成像技术和治疗方法,并确定科学里程碑和新兴研究趋势:方法:确定了 2015 年至 2023 年间发表的文献。记录了研究特点、影响因子和研究来源国。绘制热图以直观显示数据并确定领先中心。最常被引用的出版物被视为里程碑:我们筛选了 3,519 项研究。共纳入 368 项研究,其中 326 项为临床研究。临床研究又细分为介入性研究(138 项)、外科手术研究(115 项)或成像模式研究(74 项)。我们发现,全世界的科研成果大幅增加,尤其是成像和介入研究。美国、德国和波兰分别被确定为成像、介入和临床前研究的领先国家:我们的研究反映了过去 9 年中全球知识的增长。结论:我们的研究反映了过去 9 年中全球知识的增长。影像学研究也出现了快速增长,尤其是自 2020 年以来。近年来,我们发现外科手术研究有所减少。
{"title":"Bibliometric analysis of imaging and treatment strategies for severe tricuspid regurgitation from 2015 to 2023.","authors":"Johannes Schlegl, Marwin Bannehr, Tanja Kücken, Paulina Jankowska, Michael Neuss, Michael Lichtenauer, Anja Haase-Fielitz, Christian Butter, Christoph Edlinger","doi":"10.3389/fcvm.2024.1444466","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1444466","url":null,"abstract":"<p><strong>Background: </strong>Severe tricuspid regurgitation is a progressive disease with an unfavourable prognosis. In recent years there have been extraordinary gains in knowledge through both clinical and basic scientific work. We performed a bibliometric analysis on tricuspid regurgitation with a focus on imaging techniques and treatment approaches and to identify scientific milestones and emerging research trends.</p><p><strong>Methods: </strong>Publications, published between 2015 and 2023 were identified. Study characteristics, impact factors and countries of origin studies were recorded. Heat maps were created to visualise data and to identify leading centers. Most frequently cited publications were recognised as milestones.</p><p><strong>Results: </strong>We screened 3,519 studies. 368 studies were included, of which 326 were clinical studies. Clinical studies were further subdivided into interventional (<i>n</i> = 138), surgical (<i>n</i> = 115) or studies on imaging modalities (<i>n</i> = 74). We detected an enormous increase in scientific output worldwide, especially in imaging and interventional studies. The United States, Germany and Poland were identified as leading countries in imaging, interventions and preclinical studies respectively.</p><p><strong>Conclusions: </strong>Our study reflects the global gain in knowledge over the last 9 years. We were able to identify an annually rising number of interventional studies. Imaging studies have also seen a rapid increase, especially since 2020. In recent years, we monitored a decline in surgical studies.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1444466"},"PeriodicalIF":2.8,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolomics revealed pharmacodynamic effects of aspirin and indobufen in patients after percutaneous transluminal angioplasty surgery. 代谢组学揭示了阿司匹林和吲哚布芬对经皮腔内血管成形术术后患者的药效学效应。
IF 2.8 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-29 eCollection Date: 2024-01-01 DOI: 10.3389/fcvm.2024.1433643
Shaobo Sun, Kang Xun, Damei Li, Renjie Bao

Introduction: Aspirin and indobufen are commonly used therapeutic drugs for the prevention of vascular restenosis (VR) after percutaneous transluminal angioplasty surgery. They both exhibited antiplatelet effects but molecular mechanisms underlying metabolic changes induced by them remain unclear.

Methods: In this study, we collected plasma samples from patients on aspirin medication (n = 5), patients on indobufen medication, patients with no medication after PTA, and healthy controls (CKs) (n = 5). Our investigation aimed to reveal the metabolic processes in patients during vascular restenosis and its amelioration through drug therapy using liquid chromatography-tandem mass spectrometry (LC-MS/MS).

Results: Our data showed significant alterations in amino acid and choline metabolism in patients without medication after PTA. Aspirin and indobufen were able to regulate these metabolic pathways to alleviate VR symptoms. We identified several characteristic amino acids, including pro-leu, L-citrulline, his-glu, and L-glutamate, as important biomarkers for VR assessment in patients without medication after PTA. A total of 17 and 4 metabolites involved in arginine and phenylalanine metabolism were specifically induced by aspirin and indobufen, respectively. Their expression levels were significantly regulated by aspirin or indobufen, nearly reaching normal levels.

Discussion: Taken together, our identification of metabolites involved in metabolic changes affected by aspirin and indobufen medication enhances the understanding of VR pathology after PTA. This may help identify early diagnostic biomarkers and therapeutic targets.

简介:阿司匹林和吲哚布芬是预防经皮腔内血管成形术后血管再狭窄(VR)的常用治疗药物。这两种药物都具有抗血小板作用,但它们引起代谢变化的分子机制仍不清楚:在这项研究中,我们收集了服用阿司匹林药物的患者(5 人)、服用吲哚布芬药物的患者、PTA 术后未服用药物的患者以及健康对照组(5 人)的血浆样本。我们的研究旨在利用液相色谱-串联质谱法(LC-MS/MS)揭示患者血管再狭窄期间的代谢过程以及通过药物治疗改善血管再狭窄的情况:我们的数据显示,PTA 后未服药患者的氨基酸和胆碱代谢发生了明显变化。阿司匹林和吲哚布芬能够调节这些代谢途径,从而缓解 VR 症状。我们发现了几种特征性氨基酸,包括前列腺素、L-瓜氨酸、his-谷氨酰胺和 L-谷氨酸,它们是评估 PTA 后未服药患者 VR 的重要生物标记物。阿司匹林和吲哚布芬分别特异性诱导了17种和4种参与精氨酸和苯丙氨酸代谢的代谢物。它们的表达水平受到阿司匹林或吲哚布芬的明显调节,几乎达到正常水平:总之,我们对参与阿司匹林和吲哚布芬药物影响的代谢变化的代谢物的鉴定,加深了人们对 PTA 后 VR 病理的了解。这可能有助于确定早期诊断生物标志物和治疗目标。
{"title":"Metabolomics revealed pharmacodynamic effects of aspirin and indobufen in patients after percutaneous transluminal angioplasty surgery.","authors":"Shaobo Sun, Kang Xun, Damei Li, Renjie Bao","doi":"10.3389/fcvm.2024.1433643","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1433643","url":null,"abstract":"<p><strong>Introduction: </strong>Aspirin and indobufen are commonly used therapeutic drugs for the prevention of vascular restenosis (VR) after percutaneous transluminal angioplasty surgery. They both exhibited antiplatelet effects but molecular mechanisms underlying metabolic changes induced by them remain unclear.</p><p><strong>Methods: </strong>In this study, we collected plasma samples from patients on aspirin medication (<i>n</i> = 5), patients on indobufen medication, patients with no medication after PTA, and healthy controls (CKs) (<i>n</i> = 5). Our investigation aimed to reveal the metabolic processes in patients during vascular restenosis and its amelioration through drug therapy using liquid chromatography-tandem mass spectrometry (LC-MS/MS).</p><p><strong>Results: </strong>Our data showed significant alterations in amino acid and choline metabolism in patients without medication after PTA. Aspirin and indobufen were able to regulate these metabolic pathways to alleviate VR symptoms. We identified several characteristic amino acids, including pro-leu, L-citrulline, his-glu, and L-glutamate, as important biomarkers for VR assessment in patients without medication after PTA. A total of 17 and 4 metabolites involved in arginine and phenylalanine metabolism were specifically induced by aspirin and indobufen, respectively. Their expression levels were significantly regulated by aspirin or indobufen, nearly reaching normal levels.</p><p><strong>Discussion: </strong>Taken together, our identification of metabolites involved in metabolic changes affected by aspirin and indobufen medication enhances the understanding of VR pathology after PTA. This may help identify early diagnostic biomarkers and therapeutic targets.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1433643"},"PeriodicalIF":2.8,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends and patterns in pulmonary arterial hypertension-associated hospital admissions among methamphetamine users: a decade-long study. 甲基苯丙胺吸食者肺动脉高压相关住院治疗的趋势和模式:一项长达十年的研究。
IF 2.8 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-28 eCollection Date: 2024-01-01 DOI: 10.3389/fcvm.2024.1445193
Amanda Husein, Jolie Boullion, Md Ismail Hossain, Diensn Xing, Md Tareq Ferdous Khan, Md Shenuarin Bhuiyan, Gopi K Kolluru, Md Mostafizur Rahman Bhuiyan, Nicholas E Goeders, Steven A Conrad, John A Vanchiere, A Wayne Orr, Christopher G Kevil, Mohammad Alfrad Nobel Bhuiyan

Background: Pulmonary arterial hypertension (PAH) is a rare, chronic, progressive form of pulmonary hypertension in which increased arterial pressure causes remodeling of the arterial system and is associated with heart failure. Methamphetamine is a stimulant that has recently become a focus in PAH research, but the recent trends and demographics of this cohort of patients are not known. The study aimed to analyze the overall trends and demographics of PAH patients with and without concurrent methamphetamine usage.

Methods: The study used the National Inpatient Sample (NIS), Healthcare Cost and Utilization Project (HCUP), and Agency for Healthcare Research and Quality (AHRQ) from 2008 to 2020 to calculate nationally weighted estimates for both conditions by ICD-9 and ICD-10 diagnosis codes. We used several statistical measures, including descriptive statistics with design-based chi-square and t-tests, trend analysis with Cochran-Armitage test, generalized linear models, and other data preprocessing measures.

Results: A significant increase was evident in patients with pulmonary arterial hypertension (PAH) and concurrent methamphetamine use (9.2-fold). Most of the hospitalized patients were males (59.16%), aged 41-64 (45.77%), White (68.64%), from the West (53.09%), with Medicaid (50.48%), and with median income <$25,000. The rate of increase over the period was higher for males (11.8-fold), race (not sure which race; please check and modify), aged 41-64 (11.3-fold), and in the South (15.1-fold). An overall adjusted prevalence ratio (PR) for PAH hospitalizations among concurrent methamphetamine users was 32.19 (CI = 31.19-33.22) compared to non-users. With respective reference categories, the significantly higher PR was evident for males, patients aged 41-64, White, with Medicare, median income <$25,000, all regions compared to Northeast, length of hospital stays, and conditions, including chronic pulmonary disease, diabetes, hypertension, obesity, and peripheral vascular disorders.

Conclusion: This study reveals a national overall and demographic-specific trend of increasing PAH with concurrent methamphetamine usage and associated factors. The findings may help to understand the current patterns and identify the vulnerable sociodemographic cohorts for further research and to take appropriate policy measures.

背景:肺动脉高压(PAH)是一种罕见的慢性进行性肺动脉高压,动脉压力升高会导致动脉系统重塑,并与心力衰竭有关。甲基苯丙胺是一种兴奋剂,近来已成为 PAH 研究的重点,但这部分患者的近期趋势和人口统计数据尚不清楚。该研究旨在分析同时使用和未使用甲基苯丙胺的 PAH 患者的总体趋势和人口统计学特征:该研究使用了 2008 年至 2020 年的全国住院患者样本 (NIS)、医疗保健成本和利用项目 (HCUP) 以及医疗保健研究和质量局 (AHRQ),按 ICD-9 和 ICD-10 诊断代码计算了这两种病症的全国加权估计值。我们采用了多种统计方法,包括描述性统计与基于设计的卡方检验和 t 检验、趋势分析与 Cochran-Armitage 检验、广义线性模型以及其他数据预处理方法:肺动脉高压(PAH)患者和同时吸食甲基苯丙胺的患者明显增加(9.2倍)。大多数住院病人为男性(59.16%)、41-64 岁(45.77%)、白人(68.64%)、西部人(53.09%)、享受医疗补助(50.48%)和收入中位数:本研究揭示了 PAH 在全国总体和特定人口中的增长趋势,以及同时使用甲基苯丙胺和相关因素。研究结果有助于了解当前的模式,确定易受影响的社会人口群体,以便开展进一步研究并采取适当的政策措施。
{"title":"Trends and patterns in pulmonary arterial hypertension-associated hospital admissions among methamphetamine users: a decade-long study.","authors":"Amanda Husein, Jolie Boullion, Md Ismail Hossain, Diensn Xing, Md Tareq Ferdous Khan, Md Shenuarin Bhuiyan, Gopi K Kolluru, Md Mostafizur Rahman Bhuiyan, Nicholas E Goeders, Steven A Conrad, John A Vanchiere, A Wayne Orr, Christopher G Kevil, Mohammad Alfrad Nobel Bhuiyan","doi":"10.3389/fcvm.2024.1445193","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1445193","url":null,"abstract":"<p><strong>Background: </strong>Pulmonary arterial hypertension (PAH) is a rare, chronic, progressive form of pulmonary hypertension in which increased arterial pressure causes remodeling of the arterial system and is associated with heart failure. Methamphetamine is a stimulant that has recently become a focus in PAH research, but the recent trends and demographics of this cohort of patients are not known. The study aimed to analyze the overall trends and demographics of PAH patients with and without concurrent methamphetamine usage.</p><p><strong>Methods: </strong>The study used the National Inpatient Sample (NIS), Healthcare Cost and Utilization Project (HCUP), and Agency for Healthcare Research and Quality (AHRQ) from 2008 to 2020 to calculate nationally weighted estimates for both conditions by ICD-9 and ICD-10 diagnosis codes. We used several statistical measures, including descriptive statistics with design-based chi-square and <i>t</i>-tests, trend analysis with Cochran-Armitage test, generalized linear models, and other data preprocessing measures.</p><p><strong>Results: </strong>A significant increase was evident in patients with pulmonary arterial hypertension (PAH) and concurrent methamphetamine use (9.2-fold). Most of the hospitalized patients were males (59.16%), aged 41-64 (45.77%), White (68.64%), from the West (53.09%), with Medicaid (50.48%), and with median income <$25,000. The rate of increase over the period was higher for males (11.8-fold), race (not sure which race; please check and modify), aged 41-64 (11.3-fold), and in the South (15.1-fold). An overall adjusted prevalence ratio (PR) for PAH hospitalizations among concurrent methamphetamine users was 32.19 (CI = 31.19-33.22) compared to non-users. With respective reference categories, the significantly higher PR was evident for males, patients aged 41-64, White, with Medicare, median income <$25,000, all regions compared to Northeast, length of hospital stays, and conditions, including chronic pulmonary disease, diabetes, hypertension, obesity, and peripheral vascular disorders.</p><p><strong>Conclusion: </strong>This study reveals a national overall and demographic-specific trend of increasing PAH with concurrent methamphetamine usage and associated factors. The findings may help to understand the current patterns and identify the vulnerable sociodemographic cohorts for further research and to take appropriate policy measures.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1445193"},"PeriodicalIF":2.8,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11550945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Imaging human coronary cholesterol/urate crystals with cross-polarized micro-optical coherence tomography. 利用交叉偏振微光学相干断层扫描成像人体冠状动脉胆固醇/尿酸盐晶体。
IF 2.8 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-28 eCollection Date: 2024-01-01 DOI: 10.3389/fcvm.2024.1433227
Kensuke Nishimiya, Gargi Sharma, Kanwarpal Singh, Osman O Ahsen, Joseph A Gardecki, Guillermo J Tearney

Introduction: Birefringent crystals such as monosodium-urate (MSU) and cholesterol crystals (CC) likely contribute to the progression of coronary artery disease (CAD) due to their potential to exacerbate inflammation through inflammatory cytokine activation. Here, we present cross-polarized micro-optical coherence tomography (CP-µOCT) for visualizing individual birefringent crystals in human coronary arteries.

Methods and results: Human cadaver coronary arteries with a history of CAD with or without gout were dissected for CP-µOCT imaging. Specimens were processed for histological identification of birefringence under polarization light microscopy (PLM). CP-µOCT visualized needle-crystals that appeared as long projections in orthogonal planes, and PLM confirmed that CP-µOCT-delineated needle-crystals demonstrated negative birefringence. The needle-crystals were dissolved after immersion in uricase (p < 0.05), and thus were MSU. CP-µOCT was three-dimensionally volume-rendered for counting MSU and CCs in 79 regions of interest sized [750 (x) × 500 (y) × 400 (z) µm]. Crystal counts were normalized by the total coronary length utilized. The relationship between CP-µOCT-delineated MSU counts and those seen in corresponding histology, and the difference in coronary MSU amongst gout vs. non-gout patients was analyzed. CP-µOCT-delineated MSU counts were significantly correlated with MSU counted by PLM-based histology (R = 0.98, p < 0.01), and with histology-derived intimal thickening (R = 0.51, p < 0.01). MSU and CCs were both significantly greater in gout patients compared with non-gout patients (p < 0.05).

Discussion: These results demonstrate a significant increase in CP-µOCT-delineated crystals in gout vs. non-gout patients, suggesting that this technology can be used to improve our understanding of crystal-driven coronary pathogenesis.

简介:单钠尿酸盐(MSU)和胆固醇结晶(CC)等双折射晶体可能会通过激活炎症细胞因子加剧炎症,从而导致冠状动脉疾病(CAD)的恶化。在此,我们介绍了交叉偏振微光学相干断层扫描(CP-µOCT),用于观察人体冠状动脉中的单个双折射晶体:解剖有或没有痛风的 CAD 病史的人体尸体冠状动脉,进行 CP-µOCT 成像。在偏振光显微镜(PLM)下对标本进行组织学鉴定。CP-µOCT 可观察到在正交平面上呈长投影的针状晶体,偏振光显微镜证实 CP-µOCT 划线的针状晶体显示出负双折射。针状晶体浸泡在尿酸酶(p x)×500(y)×400(z)微米]中后溶解。晶体计数按所使用的冠状动脉总长度归一化。分析了 CP-µOCT 划线的 MSU 计数与相应组织学中的 MSU 计数之间的关系,以及痛风患者与非痛风患者冠状动脉 MSU 的差异。CP-µOCT 划线的 MSU 计数与基于 PLM 组织学的 MSU 计数有明显相关性(R = 0.98,p R = 0.51,p p 讨论:这些结果表明,与非痛风患者相比,痛风患者的 CP-µOCT 划线晶体数量明显增加,这表明该技术可用于加深我们对晶体驱动的冠状动脉发病机制的了解。
{"title":"Imaging human coronary cholesterol/urate crystals with cross-polarized micro-optical coherence tomography.","authors":"Kensuke Nishimiya, Gargi Sharma, Kanwarpal Singh, Osman O Ahsen, Joseph A Gardecki, Guillermo J Tearney","doi":"10.3389/fcvm.2024.1433227","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1433227","url":null,"abstract":"<p><strong>Introduction: </strong>Birefringent crystals such as monosodium-urate (MSU) and cholesterol crystals (CC) likely contribute to the progression of coronary artery disease (CAD) due to their potential to exacerbate inflammation through inflammatory cytokine activation. Here, we present cross-polarized micro-optical coherence tomography (CP-µOCT) for visualizing individual birefringent crystals in human coronary arteries.</p><p><strong>Methods and results: </strong>Human cadaver coronary arteries with a history of CAD with or without gout were dissected for CP-µOCT imaging. Specimens were processed for histological identification of birefringence under polarization light microscopy (PLM). CP-µOCT visualized needle-crystals that appeared as long projections in orthogonal planes, and PLM confirmed that CP-µOCT-delineated needle-crystals demonstrated negative birefringence. The needle-crystals were dissolved after immersion in uricase (<i>p</i> < 0.05), and thus were MSU. CP-µOCT was three-dimensionally volume-rendered for counting MSU and CCs in 79 regions of interest sized [750 (<i>x</i>) × 500 (<i>y</i>) × 400 (<i>z</i>) µm]. Crystal counts were normalized by the total coronary length utilized. The relationship between CP-µOCT-delineated MSU counts and those seen in corresponding histology, and the difference in coronary MSU amongst gout vs. non-gout patients was analyzed. CP-µOCT-delineated MSU counts were significantly correlated with MSU counted by PLM-based histology (<i>R</i> = 0.98, <i>p</i> < 0.01), and with histology-derived intimal thickening (<i>R</i> = 0.51, <i>p</i> < 0.01). MSU and CCs were both significantly greater in gout patients compared with non-gout patients (<i>p</i> < 0.05).</p><p><strong>Discussion: </strong>These results demonstrate a significant increase in CP-µOCT-delineated crystals in gout vs. non-gout patients, suggesting that this technology can be used to improve our understanding of crystal-driven coronary pathogenesis.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1433227"},"PeriodicalIF":2.8,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551715/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safe and favorable prognosis of thoracic endovascular aortic repair for the low-risk patients with non-acute type B aortic dissection. 对非急性 B 型主动脉夹层的低风险患者进行胸腔内血管主动脉修补术,安全且预后良好。
IF 2.8 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-28 eCollection Date: 2024-01-01 DOI: 10.3389/fcvm.2024.1442800
Ken Nakamura, Kimihiro Kobayashi, Shingo Nakai, Ri Sho, Shusuke Arai, Ai Ishizawa, Daisuke Watanabe, Shuto Hirooka, Eiichi Ohba, Masahiro Mizumoto, Yoshinori Kuroda, Cholsu Kim, Hideaki Uchino, Takao Shimanuki, Tetsuro Uchida

Objective: Preemptive thoracic endovascular aortic repair (TEVAR) has the potential to improve the prognosis of Stanford type B aortic dissection (TBAD), however it is important to determine whether it could be safely performed as a prophylactic treatment. This study aimed to determine the short- and long-term outcomes of preemptive TEVAR for uncomplicated TBAD with a small aortic aneurysm.

Design: Retrospective multicenter analysis.

Methods: We analyzed 212 patients with medically treated uncomplicated subacute TBAD between July 2004 and October 2019 in two Japanese academic centers. The short- and long-term prognosis of patients who underwent preemptive TEVAR and the changes in aortic diameter over time after TEVAR were analyzed. Aorta-related complications, aortic-related death and postoperative complications were recorded and analyzed. Analysis was performed on an intension-to-treat basis.

Results: During follow-up, patients were divided into two groups: optimal medical treatment [OMT; n = 185 (87%)] and preemptive TEVAR [n = 27 (13%)]. In all cases, aortic enlargement was the reason for therapeutic intervention in the preemptive TEVAR group. Propensity score matching yielded a cohort of 27 control patients with OMT (group A) and 27 patients who underwent preemptive TEVAR (group B). Preoperative characteristics were similar between groups. In group B, only one patient developed type A dissection at a late stage and died from aortic rupture. Freedom from aortic-related death at 1/5/10 years was 100%/92%/92% in group B. Overall growth (mm/year) of max aorta was significantly smaller in the TEVAR group than in the control group (-3.7 ± 2.9 vs. 0.4 ± 5.6, p < 0.01), and the diameter of the false lumen was reduced (-8 ± 4.8 vs. -1.3 ± 8.0, p < 0.001).

Conclusions: Short- and long-term outcomes of TEVAR for uncomplicated TBAD with a small aortic aneurysm were excellent, with few postoperative complications. After TEVAR, aortic remodeling was observed in the short term, suggesting that it may contribute to the prevention of aortic-related death due to rupture.

目的:先发制人的胸腔内血管主动脉修复术(TEVAR)有可能改善斯坦福B型主动脉夹层(TBAD)的预后,但重要的是确定其是否能作为预防性治疗安全实施。本研究旨在确定对伴有小主动脉瘤的无并发症TBAD进行先期TEVAR治疗的短期和长期疗效:设计:回顾性多中心分析:我们分析了2004年7月至2019年10月期间在日本两个学术中心接受药物治疗的212名无并发症亚急性TBAD患者。分析了先行 TEVAR 患者的短期和长期预后,以及 TEVAR 后主动脉直径随时间的变化。记录并分析了主动脉相关并发症、主动脉相关死亡和术后并发症。分析以意向治疗为基础:随访期间,患者被分为两组:最佳药物治疗[OMT;n = 185(87%)]和先期TEVAR[n = 27(13%)]。在所有病例中,主动脉扩大是先发制人 TEVAR 组进行治疗干预的原因。倾向得分匹配得出的队列包括 27 名接受 OMT 的对照组患者(A 组)和 27 名接受先发制人 TEVAR 的患者(B 组)。两组患者的术前特征相似。在 B 组中,只有一名患者在晚期出现 A 型夹层,死于主动脉破裂。TEVAR组的最大主动脉总体增长(毫米/年)明显小于对照组(-3.7 ± 2.9 vs. 0.4 ± 5.6,p p 结论:TEVAR治疗无并发症的TBAD和小主动脉瘤的短期和长期疗效都很好,术后并发症很少。TEVAR 术后短期内可观察到主动脉重塑,这表明 TEVAR 有助于预防主动脉破裂导致的死亡。
{"title":"Safe and favorable prognosis of thoracic endovascular aortic repair for the low-risk patients with non-acute type B aortic dissection.","authors":"Ken Nakamura, Kimihiro Kobayashi, Shingo Nakai, Ri Sho, Shusuke Arai, Ai Ishizawa, Daisuke Watanabe, Shuto Hirooka, Eiichi Ohba, Masahiro Mizumoto, Yoshinori Kuroda, Cholsu Kim, Hideaki Uchino, Takao Shimanuki, Tetsuro Uchida","doi":"10.3389/fcvm.2024.1442800","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1442800","url":null,"abstract":"<p><strong>Objective: </strong>Preemptive thoracic endovascular aortic repair (TEVAR) has the potential to improve the prognosis of Stanford type B aortic dissection (TBAD), however it is important to determine whether it could be safely performed as a prophylactic treatment. This study aimed to determine the short- and long-term outcomes of preemptive TEVAR for uncomplicated TBAD with a small aortic aneurysm.</p><p><strong>Design: </strong>Retrospective multicenter analysis.</p><p><strong>Methods: </strong>We analyzed 212 patients with medically treated uncomplicated subacute TBAD between July 2004 and October 2019 in two Japanese academic centers. The short- and long-term prognosis of patients who underwent preemptive TEVAR and the changes in aortic diameter over time after TEVAR were analyzed. Aorta-related complications, aortic-related death and postoperative complications were recorded and analyzed. Analysis was performed on an intension-to-treat basis.</p><p><strong>Results: </strong>During follow-up, patients were divided into two groups: optimal medical treatment [OMT; <i>n</i> = 185 (87%)] and preemptive TEVAR [<i>n</i> = 27 (13%)]. In all cases, aortic enlargement was the reason for therapeutic intervention in the preemptive TEVAR group. Propensity score matching yielded a cohort of 27 control patients with OMT (group A) and 27 patients who underwent preemptive TEVAR (group B). Preoperative characteristics were similar between groups. In group B, only one patient developed type A dissection at a late stage and died from aortic rupture. Freedom from aortic-related death at 1/5/10 years was 100%/92%/92% in group B. Overall growth (mm/year) of max aorta was significantly smaller in the TEVAR group than in the control group (-3.7 ± 2.9 vs. 0.4 ± 5.6, <i>p</i> < 0.01), and the diameter of the false lumen was reduced (-8 ± 4.8 vs. -1.3 ± 8.0, <i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>Short- and long-term outcomes of TEVAR for uncomplicated TBAD with a small aortic aneurysm were excellent, with few postoperative complications. After TEVAR, aortic remodeling was observed in the short term, suggesting that it may contribute to the prevention of aortic-related death due to rupture.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1442800"},"PeriodicalIF":2.8,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11550929/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Frontiers in Cardiovascular Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1